| |
Categories of adherence to MEDLIFE
|
p for trend
|
Per +2-point increment
|
|---|
|
Q1 (4–11 p)
|
Q2 (12–13 p)
|
Q3 (14–15 p)
|
Q4 (16–23 p)
|
|---|
|
All-cause mortality
|
|
N
|
3042
|
3435
|
2917
|
1696
| | |
|
Deaths
|
118
|
106
|
76
|
30
| | |
|
Person-years
|
9,716,596
|
10,978,581
|
9,323,908
|
5,381,351
| | |
|
Model 1, HR (95% CI)
|
1 Ref.
|
0.92 (0.70, 1.21)
|
0.68 (0.48, 0.95)
|
0.54 (0.36, 0.83)
|
0.004
|
0.87 (0.79, 0.96)
|
|
Model 2, HR (95% CI)
|
1 Ref.
|
0.91 (0.69, 1.22)
|
0.70 (0.49, 0.99)
|
0.55 (0.36, 0.85)
|
0.010
|
0.88 (0.80, 0.97)
|
|
Model 3, HR (95% CI)
|
1 Ref.
|
0.88 (0.65, 1.18)
|
0.68 (0.48, 0.96)
|
0.55 (0.35, 0.85)
|
0.014
|
0.88 (0.79, 0.97)
|
|
Model 4, HR (95% CI)
|
1 Ref.
|
0.92 (0.68, 1.25)
|
0.72 (0.51, 1.02)
|
0.58 (0.37, 0.90)
|
0.025
|
0.89 (0.81, 0.99)
|
|
CVD mortality
|
|
Deaths
|
29
|
21
|
19
|
5
| | |
|
Person-years
|
9,716,596
|
10,978,581
|
9,323,908
|
5,381,351
| | |
|
Model 1, HR (95% CI)
|
1 Ref.
|
0.50 (0.27, 0.93)
|
0.72 (0.37, 1.37)
|
0.26 (0.08, 0.79)
|
0.02
|
0.78 (0.64, 0.97)
|
|
Model 2, HR (95% CI)
|
1 Ref.
|
0.55 (0.29, 1.04)
|
0.82 (0.42, 1.58)
|
0.30 (0.10, 0.94)
|
0.06
|
0.82 (0.67, 1.01)
|
|
Model 3, HR (95% CI)
|
1 Ref.
|
0.55 (0.28, 1.07)
|
0.83 (0.43, 1.62)
|
0.31 (0.10, 0.94)
|
0.08
|
0.83 (0.68, 1.02)
|
|
Model 4, HR (95% CI)
|
1 Ref.
|
0.57 (0.29, 1.14)
|
0.87 (0.44, 1.70)
|
0.33 (0.11, 1.02)
|
0.11
|
0.84 (0.68, 1.04)
|
- The ENRICA cohort, June 2008 to December 2017
- Number of morbidities includes the following self-reported physician-diagnosed diseases (coronary heart disease, stroke and heart failure, osteoarthritis, rheumatoid arthritis, respiratory disease, hip fracture, urinary infection, sleep apnea, depression, Alzheimer’s disease, cirrhosis, Parkinson’s disease, stomach ulcers, intestinal polysp, cataracts, periodontal disease, cancer)
- Model 1: adjusted for sex, age, educational level (no formal or primary education, secondary education, university)
- Model 2: adjusted for Model 1 + smoking (never, former, current), total energy intake (Kcal/day), and BMI
- Model 3: Model 2 + prevalence of cancer, respiratory disease, depression, number of morbidities (excluding the previously mentioned conditions), number of drug treatments
- Model 4: Model 3 + other clinical risk factors, including abdominal obesity (waist circumference ≥ 102 cm in men, or ≥ 88 cm in women), fasting blood glucose (100–126 mg/dl and not treated with antidiabetic drugs), high blood pressure (systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg) or receiving antihypertensive drugs, triglycerides ≥ 150 mg/dl and serum high-density lipoprotein (HDL) cholesterol < 40 mg/dl in men or < 50 mg/dl in women)
- HR hazard ratio, CI confidence interval
